Efficacy & safety of high-dose rifampicin in pulmonary tuberculosis: A systematic review & meta-analysis.

ABSTRACT: Background & objectives Evidence suggests that higher doses of rifampicin aid in faster culture conversion, but its effects on unfavourable outcomes are unclear. We aimed to synthesise evidence on the efficacy and safety of high-dose rifampicin (>15 mg/kg) containing anti-tuberculosis regimen compared to a regimen with standard dose of rifampicin in adults with pulmonary tuberculosis. Methods We searched for studies from MEDLINE, Embase, Web of Science, Google Scholar, and the Cochrane Library without geographical restriction. We included randomised controlled trials that evaluated high-dose rifampicin (>15 mg/kg for 8 wk) with a six-month duration. Our outcomes of interest were sputum conversion at eight wk, mortality, treatment failure at six months, Grade 3 and Grade 4 hepatotoxicity, a

SUBMITTER: Kannabiran BP 

PROVIDER: S-EPMC12550432 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature